CN111826334A - A kind of super-long Escherichia coli and its preparation method and application - Google Patents
A kind of super-long Escherichia coli and its preparation method and application Download PDFInfo
- Publication number
- CN111826334A CN111826334A CN202010721564.XA CN202010721564A CN111826334A CN 111826334 A CN111826334 A CN 111826334A CN 202010721564 A CN202010721564 A CN 202010721564A CN 111826334 A CN111826334 A CN 111826334A
- Authority
- CN
- China
- Prior art keywords
- surfactant
- escherichia coli
- coli
- long
- ultra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 163
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 22
- 238000001514 detection method Methods 0.000 claims abstract description 15
- 239000010802 sludge Substances 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 239000002351 wastewater Substances 0.000 claims abstract description 4
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 103
- 229940106164 cephalexin Drugs 0.000 claims description 102
- 239000004094 surface-active agent Substances 0.000 claims description 47
- 230000001580 bacterial effect Effects 0.000 claims description 31
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 25
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 25
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 25
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 239000003242 anti bacterial agent Substances 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 14
- 229940088710 antibiotic agent Drugs 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 238000002835 absorbance Methods 0.000 claims description 7
- 229940041514 candida albicans extract Drugs 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000012137 tryptone Substances 0.000 claims description 7
- 239000012138 yeast extract Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 239000002736 nonionic surfactant Substances 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- 239000003093 cationic surfactant Substances 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 8
- 230000009471 action Effects 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 5
- 206010057249 Phagocytosis Diseases 0.000 abstract description 3
- 230000002411 adverse Effects 0.000 abstract description 3
- 239000000427 antigen Substances 0.000 abstract description 3
- 102000036639 antigens Human genes 0.000 abstract description 3
- 108091007433 antigens Proteins 0.000 abstract description 3
- 230000008782 phagocytosis Effects 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 238000001556 precipitation Methods 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 32
- 230000000694 effects Effects 0.000 description 19
- 210000000170 cell membrane Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108700020474 Penicillin-Binding Proteins Proteins 0.000 description 2
- 230000027151 SOS response Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 238000011369 optimal treatment Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000001485 positron annihilation lifetime spectroscopy Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F3/00—Biological treatment of water, waste water, or sewage
- C02F3/34—Biological treatment of water, waste water, or sewage characterised by the microorganisms used
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- G01N2333/245—Escherichia (G)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Hydrology & Water Resources (AREA)
- Environmental & Geological Engineering (AREA)
- Water Supply & Treatment (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
技术领域technical field
本发明属于生物技术领域,涉及一种超长大肠杆菌及其制备方法与应用。The invention belongs to the field of biotechnology, and relates to a super-long Escherichia coli and a preparation method and application thereof.
背景技术Background technique
在许多科学研究领域内,细菌大小对细菌检测有重要影响,如氧化应激检测、运动性和趋化性研究、抗生素敏感性、单细胞检测和整体成像分析等。因为较大的细菌有更多表面抗原和结合位点,从而可提高检测灵敏度。此外,超长大肠杆菌的形成对活性污泥法处理污水起到重要作用,在活性污泥中超长大肠杆菌可以充当骨架的作用,保证污泥絮体的强度,提高污泥的沉淀性能,影响出水的净化效率。再者,超长大肠杆菌是分裂期缺陷导致的细胞分裂而不断裂产物,具有更强的抗吞噬、抵御不良环境的能力,比正常形态的细菌具有更强摄取食物的能力,存活率比正常细胞高。In many fields of scientific research, bacterial size has a significant impact on bacterial detection, such as oxidative stress detection, motility and chemotaxis studies, antibiotic susceptibility, single-cell detection, and overall imaging analysis. Detection sensitivity is improved because larger bacteria have more surface antigens and binding sites. In addition, the formation of ultra-long E. coli plays an important role in the treatment of sewage by activated sludge process. In activated sludge, ultra-long E. coli can act as a skeleton to ensure the strength of the sludge flocs, improve the sedimentation performance of the sludge, and affect the Purification efficiency of effluent. Furthermore, superlong Escherichia coli is the product of cell division without cleavage caused by fission phase defects. It has stronger resistance to phagocytosis and resistance to adverse environments. It has a stronger ability to ingest food than normal bacteria, and its survival rate is higher than normal. Cells are high.
据报道,SOS反应、DNA损伤、高压和脱水等不利环境压力都会导致超长大肠杆菌的形成。已有研究证明,抗生素可以促进大肠杆菌变长,如头孢氨苄。头孢氨苄诱导形成超长大肠杆菌的机制有两种,第一种是通过与细胞壁上的青霉素结合蛋白(PBPs)结合来抑制肽聚糖层的交联形成和细胞壁的合成,从而导致细胞壁生长而不分裂;第二种可能的机制是头孢氨苄的抗生素效应引起的SOS反应,导致细胞膜和细胞壁不完整。头孢氨苄的浓度也会影响大肠杆菌的延长效果,当头孢氨苄的浓度低于最小抑菌浓度时可以形成超长大肠杆菌,但当浓度较高时则会导致细菌失活。虽然抗生素可诱导形成超长大肠杆菌,但这仅考虑到了抗生素的单方面作用,且仅用抗生素延长大肠杆菌的长度还不能够满足目前科学研究的需求。Adverse environmental stresses such as SOS reaction, DNA damage, high pressure, and dehydration have been reported to lead to the formation of ultralong E. coli. Studies have shown that antibiotics can promote the growth of E. coli, such as cephalexin. There are two mechanisms by which cephalexin induces the formation of ultra-long E. coli. The first is to inhibit the formation of cross-links of the peptidoglycan layer and the synthesis of the cell wall by binding to penicillin-binding proteins (PBPs) on the cell wall, resulting in the growth of the cell wall. Does not divide; a second possible mechanism is the SOS response caused by the antibiotic effect of cephalexin, resulting in incomplete cell membranes and cell walls. The concentration of cephalexin also affects the elongation effect of E. coli. When the concentration of cephalexin is lower than the minimum inhibitory concentration, ultra-long E. coli can be formed, but when the concentration is higher, it will lead to bacterial inactivation. Although antibiotics can induce the formation of ultra-long Escherichia coli, this only takes into account the unilateral effect of antibiotics, and only prolonging the length of Escherichia coli with antibiotics cannot meet the needs of current scientific research.
UV光照是形成超长大肠杆菌的物理方法,它是通过持续的UV照射破坏或抑制细胞内DNA的复制后,激活特定基因并诱导SOS反应。SOS反应可以抑制细菌分裂,让细菌只生长而不分裂,从而形成超长大肠杆菌。UV光的类型,光照强度、时间及频率等都会影响超长大肠杆菌的形成。通过UV照射所产生的超长大肠杆菌由于DNA受到了损伤,所以存活率较低,而且遗传性较差,一旦损伤的DNA被修复后,细胞的分裂能力就会慢慢恢复。UV irradiation is a physical method to form ultralong E. coli, which activates specific genes and induces SOS response after damaging or inhibiting the replication of intracellular DNA through continuous UV irradiation. The SOS reaction can inhibit bacterial division, allowing bacteria to only grow without dividing, thereby forming superlong E. coli. The type of UV light, light intensity, time and frequency will affect the formation of ultra-long E. coli. The ultra-long E. coli produced by UV irradiation has a low survival rate due to DNA damage, and has poor heritability. Once the damaged DNA is repaired, the cell division ability will slowly recover.
因此,本发明制备超长大肠杆菌的方法对于细菌检测、处理废水以及其他对细菌存活率有要求的科学研究均具有重大价值。Therefore, the method for preparing ultra-long Escherichia coli of the present invention has great value for bacterial detection, wastewater treatment and other scientific researches that require bacterial survival rate.
发明内容SUMMARY OF THE INVENTION
为了克服现有技术的缺点与不足,本发明的首要目的在于提供一种超长大肠杆菌的制备方法。In order to overcome the shortcomings and deficiencies of the prior art, the primary purpose of the present invention is to provide a method for preparing ultra-long Escherichia coli.
本发明的另一目的在于提供通过上述制备方法制备得到的超长大肠杆菌Another object of the present invention is to provide ultralong Escherichia coli prepared by the above preparation method
本发明的再一目的在于提供上述超长大肠杆菌的应用。Another object of the present invention is to provide the application of the above-mentioned ultra-long Escherichia coli.
本发明的目的通过下述技术方案实现:一种超长大肠杆菌的制备方法,包括如下步骤:The object of the present invention is achieved through the following technical solutions: a preparation method of ultra-long Escherichia coli, comprising the steps:
(1)将大肠杆菌接种到培养基中,培养,稀释,再培养;(1) inoculate Escherichia coli into the medium, cultivate, dilute, and cultivate again;
(2)将步骤(1)再培养后的大肠杆菌接种到含有表面活性剂和头孢氨苄的培养基中,培养,得到超长大肠杆菌。(2) inoculating the Escherichia coli after recultivation in step (1) into a medium containing surfactant and cephalexin, and culturing to obtain ultralong Escherichia coli.
步骤(1)中所述的大肠杆菌在使用前通过基因工程的方法使其具备除头孢氨苄之外的其他抗生素的抗性,或直接使用具有其他抗生素抗性的大肠杆菌,并且在培养过程中添加适量的该抗生素。Escherichia coli described in the step (1) is made to have resistance to other antibiotics except cephalexin by the method of genetic engineering before use, or directly use Escherichia coli with other antibiotic resistance, and in the culturing process. Add the appropriate amount of this antibiotic.
步骤(1)中所述的大肠杆菌优选为E.coli TOP 10、E.coli pD1B10、E.coli BL21、E.coli MG1655中的一种;更优选为E.coli TOP 10。The Escherichia coli described in step (1) is preferably one of E.coli
步骤(1)中所述的培养基为pH值为7.0的LB培养基。The medium described in step (1) is LB medium with a pH value of 7.0.
所述的LB培养基的配方:10g/L氯化钠、5g/L酵母提取物和10g/L胰蛋白胨。The formulation of the LB medium: 10 g/L sodium chloride, 5 g/L yeast extract and 10 g/L tryptone.
步骤(1)中所述的培养为37℃培养12h,至吸光值OD=0.5。The culture described in step (1) is 37° C. for 12 hours until the absorbance value OD=0.5.
步骤(1)中所述的稀释为稀释1000倍。The dilution described in step (1) is 1000-fold dilution.
步骤(1)中所述的再培养为37℃培养2h。The re-cultivation described in step (1) is 37° C. for 2 h.
步骤(2)中所述的头孢氨苄的用量为按其在培养基中浓度为30-120μg/mL配比;优选为60-100μg/mL;更优选为60-90μg/mL。The dosage of cephalexin described in the step (2) is 30-120 μg/mL according to its concentration in the culture medium; preferably 60-100 μg/mL; more preferably 60-90 μg/mL.
步骤(2)中所述的表面活性剂优选为阳离子表面活性剂CTAB、阴离子表面活性剂SDS和非离子表面活性剂Tween。The surfactants described in step (2) are preferably cationic surfactant CTAB, anionic surfactant SDS and nonionic surfactant Tween.
所述的非离子表面活性剂Tween优选为Tween-20。The nonionic surfactant Tween is preferably Tween-20.
所述的表面活性剂为CTAB时,其用量为按其在培养基中浓度为质量比0.0005-0.02%配比;优选为按其在培养基中浓度为质量比0.0005-0.002%配比;更优选为按其在培养基中浓度为质量比0.001%配比。When the surfactant is CTAB, its dosage is 0.0005-0.02% by mass according to its concentration in the culture medium; preferably, it is 0.0005-0.002% by mass according to its concentration in the culture medium; Preferably, it is formulated according to its concentration in the medium as a mass ratio of 0.001%.
所述的表面活性剂为SDS时,其用量为按其在培养基中浓度为质量比0.005-0.5%配比;优选为按其在培养基中浓度为质量比0.1%配比。When the surfactant is SDS, its dosage is 0.005-0.5% by mass according to its concentration in the medium; preferably, it is 0.1% by mass according to its concentration in the medium.
所述的表面活性剂为Tween-20时,其用量为按其在培养基中浓度为质量比0.02-10%配比;优选为按其在培养基中浓度为1-2%配比。When the surfactant is Tween-20, its dosage is 0.02-10% by mass according to its concentration in the medium; preferably, it is 1-2% according to its concentration in the medium.
步骤(2)中所述的培养为37℃培养4-8h;优选为4h。The culturing in step (2) is 37°C for 4-8 hours; preferably 4 hours.
步骤(1)和(2)的培养、再培养过程中,摇菌采用250mL锥形瓶时,摇菌的速度优选为60rpm。During the culturing and re-cultivation of steps (1) and (2), when a 250 mL conical flask is used for shaking the bacteria, the speed of shaking the bacteria is preferably 60 rpm.
一种超长大肠杆菌,通过上述制备方法制备得到。An ultra-long Escherichia coli is prepared by the above preparation method.
上述超长大肠杆菌在活性污泥法处理废水中的应用。The application of the above-mentioned ultra-long Escherichia coli in the treatment of wastewater by an activated sludge process.
上述超长大肠杆菌在细菌检测中的应用。Application of the above-mentioned ultra-long Escherichia coli in bacterial detection.
本发明相对于现有技术,具有如下的优点及效果:Compared with the prior art, the present invention has the following advantages and effects:
1、本发明的方法制备的超长大肠杆菌在活性污泥中可以充当骨架的作用,保证污泥絮体的强度,提高污泥的沉淀性能,影响出水的净化效率。因此本发明可以广泛应用于活性污泥法处理废水中。1. The ultra-long Escherichia coli prepared by the method of the present invention can act as a skeleton in the activated sludge, ensure the strength of the sludge flocs, improve the sedimentation performance of the sludge, and affect the purification efficiency of the effluent. Therefore, the present invention can be widely used in the treatment of wastewater by the activated sludge method.
2、细菌大小的增加对细菌检测有重要影响,如氧化应激检测、运动性和趋化性研究、抗生素敏感性、单细胞检测和整体成像分析等。较大的细菌,有更多表面抗原和结合位点,从而可提高检测灵敏度。因此经过本发明的方法获得的超长大肠杆菌可以广泛应用于细菌检测中。2. The increase in bacterial size has important effects on bacterial detection, such as oxidative stress detection, motility and chemotaxis studies, antibiotic susceptibility, single-cell detection and overall imaging analysis. Larger bacteria have more surface antigens and binding sites, which increases detection sensitivity. Therefore, the ultra-long Escherichia coli obtained by the method of the present invention can be widely used in bacterial detection.
3、超长大肠杆菌比正常形态的细菌具有更强摄取食物的能力,同时还具备更强的抵御外界不良危险、抗吞噬的能力,细菌培养过程中超长大肠杆菌的存活率要比正常细胞高。因此经过本发明的方法获得的超长大肠杆菌可以广泛应用于对细菌存活率有要求的科学研究中。3. Ultra-long E. coli has a stronger ability to ingest food than normal bacteria, and also has a stronger ability to resist external dangers and phagocytosis. The survival rate of ultra-long E. coli during bacterial culture is higher than that of normal cells. . Therefore, the ultra-long Escherichia coli obtained by the method of the present invention can be widely used in scientific research requiring bacterial survival rate.
4、与仅用抗生素产生的超长大肠杆菌相比,表面活性剂与抗生素联合作用产生的超长大肠杆菌更长,最长约为头孢氨苄单独作用时的3倍;同时,本发明技术考虑到了多环境因素的共同作用,比考虑头孢氨苄单独作用更具有现实意义和实际操作性。4. Compared with the super-long Escherichia coli produced only with antibiotics, the super-long Escherichia coli produced by the combined action of surfactants and antibiotics is longer, and the longest is about 3 times that when cephalexin acts alone; at the same time, the technology of the present invention considers When it comes to the joint action of multiple environmental factors, it is more realistic and practical than considering the single action of cephalexin.
5、UV处理法会导致大肠杆菌DNA损伤,造成基因突变,而本方法原理上不会造成DNA损伤进而降低基因突变的概率。与UV技术产生的超长大肠杆菌相比,表面活性剂与抗生素联合作用产生的超长大肠杆菌具有正常的DNA分布状态和更高的存活率。5. The UV treatment method will cause DNA damage in Escherichia coli, resulting in gene mutation, while this method will not cause DNA damage in principle and thus reduce the probability of gene mutation. Compared with the ultra-long E. coli produced by UV technology, the ultra-long E. coli produced by the combination of surfactants and antibiotics has a normal DNA distribution state and a higher survival rate.
附图说明Description of drawings
图1是实施例1-3的实验流程图。FIG. 1 is an experimental flow chart of Examples 1-3.
图2用不同浓度CTAB与90μg/mL头孢氨苄联合处理大肠杆菌得到的10个最长大肠杆菌的长度统计图。Fig. 2 The length statistics of the 10 longest E. coli obtained by treating E. coli with different concentrations of CTAB in combination with 90 μg/mL cephalexin.
图3用不同浓度SDS与90μg/mL头孢氨苄联合处理大肠杆菌得到的10个最长大肠杆菌的长度统计图。Fig. 3 is a graph of the length statistics of the 10 longest E. coli obtained by treating E. coli with different concentrations of SDS and 90 μg/mL cephalexin.
图4是用不同浓度Tween-20与90μg/mL头孢氨苄联合处理大肠杆菌得到的10个最长大肠杆菌的长度统计图。Figure 4 is a graph showing the length statistics of the 10 longest E. coli obtained by treating E. coli with different concentrations of Tween-20 in combination with 90 μg/mL cephalexin.
图5是超长大肠杆菌中DNA的分布图;其中,a为头孢氨苄和表面活性剂处理后的大肠杆菌DNA;b为a中白色方块内区域的放大图像;a的比例尺长度为3μm;b的比例尺长度为5μm。Fig. 5 is the distribution map of DNA in superlong E. coli; wherein, a is E. coli DNA treated with cephalexin and surfactant; b is an enlarged image of the area within the white square in a; the scale bar length of a is 3 μm; b The scale bar length is 5 μm.
图6是超长大肠杆菌中细胞膜的分布图;其中,a为头孢氨苄和表面活性剂处理后的大肠杆菌细胞膜;b为a中白色方块内区域的放大图像;a的比例尺长度为3μm;b的比例尺长度为5μm。Figure 6 is the distribution diagram of the cell membrane in superlong Escherichia coli; wherein, a is the E. coli cell membrane treated with cephalexin and surfactant; b is the enlarged image of the area inside the white square in a; the scale bar length of a is 3 μm; b The scale bar length is 5 μm.
图7是未处理、头孢氨苄处理、头孢氨苄和表面活性剂(CTAB、SDS和Tween-20)处理的大肠杆菌的Zeta电位统计图。Figure 7 is a graph of Zeta potential statistics of untreated, cephalexin treated, cephalexin and surfactant (CTAB, SDS and Tween-20) treated E. coli.
图8是不同浓度头孢氨苄处理后获得的超长大肠杆菌的长度统计图;其中,细菌的长度显示为黑点,各组数据标准差的平均值用横线表示。Figure 8 is a graph showing the length statistics of ultra-long Escherichia coli obtained after treatment with different concentrations of cephalexin; wherein, the length of bacteria is shown as black dots, and the average value of the standard deviation of each group of data is shown by a horizontal line.
图9为采用浓度为90μg/mL的头孢氨苄培养不同时间的大肠杆菌显微镜图;其中,a为培养0h;b为培养4h;c为培养8h。Fig. 9 is a microscope view of Escherichia coli cultured for different time with cephalexin at a concentration of 90 μg/mL; wherein, a is cultured for 0 h; b is cultured for 4 hours; c is cultured for 8 hours.
图10是头孢氨苄处理后的大肠杆菌电镜图;其中,标尺为60μm。Figure 10 is an electron microscope image of Escherichia coli treated with cephalexin; the scale bar is 60 μm.
图11是不同大肠杆菌品系制备超长大肠杆菌所需头孢氨苄的浓度统计图。Figure 11 is a statistical graph of the concentration of cephalexin required for the preparation of ultralong Escherichia coli by different Escherichia coli strains.
具体实施方式Detailed ways
下面结合实施例及附图对本发明作进一步详细的描述,但本发明的实施方式不限于此。The present invention will be described in further detail below with reference to the embodiments and the accompanying drawings, but the embodiments of the present invention are not limited thereto.
下列实施例中未注明具体条件的实验方法,通常按照常规条件或按照制造厂商所建议的条件。除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。In the following examples, the experimental methods without specific conditions are usually in accordance with conventional conditions or in accordance with the conditions suggested by the manufacturer. Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art.
本发明中未标注的试剂和原料均为市场上购买所得。The reagents and raw materials not marked in the present invention are all obtained from the market.
实施例1 CTAB制造超长大肠杆菌Example 1 Production of ultralong Escherichia coli by CTAB
CTAB为白色或浅黄色固态物质,易溶于异丙醇,可溶于水,具有良好的生物降解和杀菌性能,采用水配制CTAB溶液,使其浓度在培养基中依次为0.0005%(w/w)、0.001%(w/w)、0.002%(w/w)、0.005%(w/w)、0.01%(w/w)和0.02%(w/w)。CTAB is a white or light yellow solid substance, easily soluble in isopropanol, soluble in water, and has good biodegradation and bactericidal properties. The CTAB solution was prepared with water, and its concentration in the medium was 0.0005% (w/ w), 0.001% (w/w), 0.002% (w/w), 0.005% (w/w), 0.01% (w/w) and 0.02% (w/w).
①将大肠杆菌E.coli TOP 10接种到含有10g/L氯化钠、5g/L酵母提取物和10g/L胰蛋白胨,pH值为7.0的LB培养基中,并在37℃、60rpm有氧条件下过夜培养12h(采用250mL锥形瓶,下同)。①Inoculate
②将培养12h且吸光值为0.5(OD=0.5)的菌液用培养基稀释1000倍,将稀释的大肠杆菌接种到LB培养基中,37℃、60rpm有氧再培养2h。② Dilute the bacterial liquid cultured for 12 hours and the absorbance value is 0.5 (OD=0.5) by 1000 times with the medium, inoculate the diluted E.
③将②中再培养后的大肠杆菌分别接种到0.0005%(w/w)CTAB+90μg/mL头孢氨苄、0.001%(w/w)CTAB+90μg/mL头孢氨苄、0.002%(w/w)CTAB+90μg/mL头孢氨苄、0.005%(w/w)CTAB+90μg/mL头孢氨苄、0.01%(w/w)CTAB+90μg/mL头孢氨苄和0.02%(w/w)CTAB+90μg/mL头孢氨苄的培养基中,37℃、60rpm有氧培养4h,培养结束后分别测量细菌长度。对照设置:不添加头孢氨苄和CTAB(WT)的阴性对照、添加90μg/mL头孢氨苄(Cex)的阳性对照。实验流程图见图1。③ Inoculate the E. coli after re-cultivation in ② to 0.0005% (w/w) CTAB+90 μg/mL cephalexin, 0.001% (w/w) CTAB+90 μg/mL cephalexin, 0.002% (w/w) CTAB + 90 μg/mL cephalexin, 0.005% (w/w) CTAB + 90 μg/mL cephalexin, 0.01% (w/w) CTAB + 90 μg/mL cephalexin and 0.02% (w/w) CTAB + 90 μg/mL In the medium of cephalexin, aerobic cultivation was performed at 37°C and 60 rpm for 4 h, and the bacterial lengths were measured after the cultivation. Control settings: negative control without addition of cephalexin and CTAB (WT), positive control with addition of 90 μg/mL cephalexin (Cex). The experimental flow chart is shown in Figure 1.
实施例2 SDS制造超长大肠杆菌Example 2 SDS production of ultra-long Escherichia coli
SDS是一种白色或淡黄色微粘物,易溶于水,具有良好的乳化和去污性能。由于SDS在水中的最大浓度受到溶解度的限制,所以使用的浓度都不会很高,采用水配制的溶液使其浓度在培养基中分别为0.005%(w/w)、0.02%(w/w)、0.05%(w/w)、0.1%(w/w)、0.2%(w/w)和0.5%(w/w)。SDS is a white or light yellow micro-sticky substance that is easily soluble in water and has good emulsifying and decontamination properties. Since the maximum concentration of SDS in water is limited by its solubility, the concentrations used are not very high. The solutions prepared with water have concentrations of 0.005% (w/w) and 0.02% (w/w) in the medium, respectively. ), 0.05% (w/w), 0.1% (w/w), 0.2% (w/w) and 0.5% (w/w).
①将大肠杆菌接种到含有10g/L氯化钠、5g/L酵母提取物和10g/L胰蛋白胨,pH值为7.0的LB培养基中,并在37℃、60rpm有氧条件下过夜培养12h(采用250mL锥形瓶,下同)。①Escherichia coli was inoculated into LB medium containing 10g/L sodium chloride, 5g/L yeast extract and 10g/L tryptone, pH 7.0, and cultured overnight at 37°C and 60rpm under aerobic conditions for 12h (Use a 250mL conical flask, the same below).
②将培养12h且吸光值为0.5(OD=0.5)的菌液用培养基稀释1000倍,将稀释的大肠杆菌接种到LB培养基中,37℃、60rpm有氧再培养2h。② Dilute the bacterial liquid cultured for 12 hours and the absorbance value is 0.5 (OD=0.5) by 1000 times with the medium, inoculate the diluted E.
③将②中再培养后的大肠杆菌分别接种到0.005%(w/w)SDS+90μg/mL头孢氨苄、0.02%(w/w)SDS+90μg/mL头孢氨苄、0.05%(w/w)SDS+90μg/mL头孢氨苄、0.1%(w/w)SDS+90μg/mL头孢氨苄、0.2%(w/w)SDS+90μg/mL头孢氨苄和0.5%(w/w)SDS+90μg/mL头孢氨苄的培养基中,37℃、60rpm有氧培养4h,培养结束后分别测量细菌长度。对照设置:不添加头孢氨苄和SDS(WT)的阴性对照、添加90μg/mL头孢氨苄(Cex)的阳性对照。③ Inoculate the E. coli after re-cultivation in ② to 0.005% (w/w) SDS+90 μg/mL cephalexin, 0.02% (w/w) SDS+90 μg/mL cephalexin, 0.05% (w/w) SDS + 90 μg/mL cephalexin, 0.1% (w/w) SDS + 90 μg/mL cephalexin, 0.2% (w/w) SDS + 90 μg/mL cephalexin and 0.5% (w/w) SDS + 90 μg/mL In the medium of cephalexin, aerobic cultivation was performed at 37°C and 60 rpm for 4 h, and the bacterial lengths were measured after the cultivation. Control settings: negative control without addition of cephalexin and SDS (WT), positive control with addition of 90 μg/mL cephalexin (Cex).
实施例3Tween-20制造超长大肠杆菌Example 3 Tween-20 manufactures ultralong Escherichia coli
Tween-20由于分子式含有较多亲水基团,所以具有很强的亲水性能,常作为水包油(O/W)型乳化剂,可与其他乳化剂联用,增强乳化剂的稳定性。由于Tween-20的毒性小,所以配制的浓度比CTAB和SDS都要高(采用水配制),分别使其在培养基中为0.02%、0.1%、0.2%(w/w)、1%(w/w)、2%(w/w)和10%(w/w)这六种浓度。Tween-20 has strong hydrophilic properties because its molecular formula contains many hydrophilic groups. It is often used as an oil-in-water (O/W) emulsifier and can be used in combination with other emulsifiers to enhance the stability of the emulsifier. . Due to the low toxicity of Tween-20, the concentration of Tween-20 is higher than that of CTAB and SDS (prepared in water). w/w), 2% (w/w) and 10% (w/w) six concentrations.
①将大肠杆菌接种到含有10g/L氯化钠、5g/L酵母提取物和10g/L胰蛋白胨,pH值为7.0的LB培养基中,并在37℃、60rpm有氧条件下过夜培养12h(采用250mL锥形瓶,下同)。①Escherichia coli was inoculated into LB medium containing 10g/L sodium chloride, 5g/L yeast extract and 10g/L tryptone, pH 7.0, and cultured overnight at 37°C and 60rpm under aerobic conditions for 12h (Use a 250mL conical flask, the same below).
②将培养12h且吸光值为0.5(OD=0.5)的菌液用培养基稀释1000倍,将稀释的大肠杆菌接种到LB培养基中,37℃、60rpm有氧再培养2h。② Dilute the bacterial liquid cultured for 12 hours and the absorbance value is 0.5 (OD=0.5) by 1000 times with the medium, inoculate the diluted E.
③将②中再培养后的大肠杆菌分别接种到0.02%(w/w)Tween-20+90μg/mL头孢氨苄、0.1%(w/w)Tween-20+90μg/mL头孢氨苄、0.2%(w/w)Tween-20+90μg/mL头孢氨苄、1%(w/w)Tween-20+90μg/mL头孢氨苄、2%(w/w)Tween-20+90μg/mL头孢氨苄和10%(w/w)Tween-20+90μg/mL头孢氨苄培养基中,37℃、60rpm有氧培养4h,培养结束后分别测量细菌长度。对照设置:不添加头孢氨苄和Tween-20(WT)的阴性对照、添加90μg/mL头孢氨苄(Cex)的阳性对照。③ Inoculate the Escherichia coli after re-cultivation in ② to 0.02% (w/w) Tween-20+90 μg/mL cephalexin, 0.1% (w/w) Tween-20+90 μg/mL cephalexin, 0.2% (w/w) Tween-20+90 μg/mL cephalexin, respectively. w/w) Tween-20 + 90 μg/mL cephalexin, 1% (w/w) Tween-20 + 90 μg/mL cephalexin, 2% (w/w) Tween-20 + 90 μg/mL cephalexin and 10% (w/w) Tween-20+90μg/mL cephalexin medium, 37 ℃, 60rpm aerobic culture for 4h, the length of bacteria were measured after the end of the culture. Control settings: negative control without addition of cephalexin and Tween-20 (WT), positive control with addition of 90 μg/mL cephalexin (Cex).
实施例4超长大肠杆菌表征Example 4 Characterization of ultralong Escherichia coli
(1)超长大肠杆菌平均长度计算(1) Calculation of the average length of ultra-long Escherichia coli
根据以下三种假设:1)表面活性剂不改变大肠杆菌表面的电荷,2)电荷沿大肠杆菌均匀分布,3)大肠杆菌呈棒状柱状,分别计算出头孢氨苄、头孢氨苄和表面活性剂处理过的大肠杆菌样品(实施例1-3)的平均长度。According to the following three hypotheses: 1) the surfactant does not change the charge on the surface of E. coli, 2) the charge is uniformly distributed along the E. coli, and 3) the E. coli is in the shape of a rod-shaped column, the calculation of cephalexin, cephalexin and surfactant-treated The average length of the E. coli samples (Examples 1-3).
计算方法:Calculation method:
电泳迁移率与大肠杆菌电荷的关系:Q=6πηrμ (1)The relationship between electrophoretic mobility and E. coli charge: Q=6πηrμ (1)
zeta电位z与电泳迁移率的关系为: The relationship between zeta potential z and electrophoretic mobility is:
(1)式和(2)合并得zeta电位z与大肠杆菌电荷的关系:Q=4πrεzf(ka)(3)The relationship between the zeta potential z and the charge of Escherichia coli is obtained by combining formula (1) and (2): Q=4πrεzf(ka)(3)
假设大肠杆菌是一个直径为d,长度为L,比值为n=L/d的圆柱体,扩散系数D为: Assuming that E. coli is a cylinder of diameter d, length L, and ratio n=L/d, the diffusion coefficient D is:
根据爱因斯坦-斯托克斯关系: According to the Einstein-Stokes relationship:
合并式(4)(5)得: Combining equations (4) and (5), we get:
假设电荷沿着大肠杆菌均匀分布,得:Q=Adn (7)Assuming that the charge is uniformly distributed along E. coli, we get: Q=Adn (7)
合并式(3)(6)(7)得: Combine formulas (3) (6) (7) to get:
根据式(8)最终得zeta电位z与大肠杆菌长度的关系式:According to formula (8), the relationship between the zeta potential z and the length of Escherichia coli is finally obtained:
式中:Q是大肠杆菌的净电荷,η是水的粘度,r是大肠杆菌的水动力半径,μ是电泳迁移率。ε是水的介电常数,f(ka)是亨利函数(根据斯莫鲁乔夫斯基近似,它是1.5)。k是玻尔兹曼常数,T是绝对温度。where Q is the net charge of E. coli, η is the viscosity of water, r is the hydrodynamic radius of E. coli, and μ is the electrophoretic mobility. ε is the permittivity of water and f(ka) is the Henry function (according to the Smoluchowski approximation, it is 1.5). k is the Boltzmann constant and T is the absolute temperature.
由最终式可知,zeta电位z与n有关,且n=L/d,所以其实大肠杆菌细胞表面的zeta电位z与细菌长度成正相关,即细胞表面的zeta电位就越高细菌就会越长It can be seen from the final formula that the zeta potential z is related to n, and n=L/d, so in fact, the zeta potential z on the E. coli cell surface is positively correlated with the length of the bacteria, that is, the higher the zeta potential on the cell surface, the longer the bacteria.
实施例1中制备的大肠杆菌长度见图2,从图可以看出,浓度为0.005%(w/w)和0.02%(w/w)的CTAB与头孢氨苄联合制造的大肠杆菌的平均长度比头孢氨苄单独制造的大肠杆菌还要略短,其中0.005%(w/w)CTAB的延长效果最不理想。浓度为0.0005%(w/w)、0.001%(w/w)、0.002%(w/w)和0.01%(w/w)的CTAB都增强了头孢氨苄延长大肠杆菌的效果,其中0.001%(w/w)增强效果最好,约为头孢氨苄(Cex)单独作用时的1.5倍。The length of Escherichia coli prepared in Example 1 is shown in Figure 2. It can be seen from the figure that the average length ratio of the Escherichia coli produced in combination with CTAB and cephalexin at a concentration of 0.005% (w/w) and 0.02% (w/w) The E. coli produced by cephalexin alone was slightly shorter, and the prolongation effect of 0.005% (w/w) CTAB was the least ideal. CTAB at concentrations of 0.0005% (w/w), 0.001% (w/w), 0.002% (w/w) and 0.01% (w/w) all enhanced the effect of cephalexin in prolonging E. coli, with 0.001% ( w/w) the enhancement effect was the best, about 1.5 times that of cephalexin (Cex) alone.
实施例2中制备的大肠杆菌长度见图3,由图可得知,五种不同浓度的SDS都增强了头孢氨苄延长大肠杆菌的效果,其中0.5%(w/w)的增强效果最不明显,0.1%(w/w)SDS的增强效果最好,约为头孢氨苄单独作用时的2倍。同时还可以看出0.05%(w/w)和0.2%(w/w)的延长效果相当约为头孢氨苄单独作用时的1.8倍,且0.005%(w/w)的延长效果要比0.02%(w/w)更明显。The length of Escherichia coli prepared in Example 2 is shown in Figure 3. It can be seen from the figure that five different concentrations of SDS have enhanced the effect of cephalexin in extending Escherichia coli, and the enhancement effect of 0.5% (w/w) is the least obvious. , 0.1% (w/w) SDS had the best enhancement effect, which was about 2 times that of cephalexin alone. At the same time, it can also be seen that the prolongation effect of 0.05% (w/w) and 0.2% (w/w) is equivalent to about 1.8 times that of cephalexin alone, and the prolongation effect of 0.005% (w/w) is higher than that of 0.02%. (w/w) more obvious.
实施例3中制备的大肠杆菌长度见图4,从图中可知,不同浓度Tween-20对头孢氨苄延长大肠杆菌都有增强效果,且延长效果存在显著差异。0.02%(w/w)、0.1%和0.2%(w/w)的Tween-20增强头孢氨苄延长大肠杆菌的效果相似,且长度分布都较均匀。1%(w/w)和2%(w/w)的Tween-20对大肠杆菌的延长效果都很显著,其中1%(w/w)Tween-20的延长效果最好,约为头孢氨苄单独作用时的3倍。The length of Escherichia coli prepared in Example 3 is shown in Figure 4. As can be seen from the figure, different concentrations of Tween-20 have enhancement effects on the extension of Escherichia coli by cephalexin, and there are significant differences in the extension effects. 0.02% (w/w), 0.1% and 0.2% (w/w) Tween-20 had similar effects on enhancing the elongation of E. coli by cephalexin, and the length distributions were all uniform. Both 1% (w/w) and 2% (w/w) Tween-20 have significant elongation effects on E. coli, and 1% (w/w) Tween-20 has the best elongation effect, which is about cephalexin 3 times when acting alone.
(2)超长大肠杆菌细胞膜完整性和DNA分布(2) Membrane integrity and DNA distribution of ultralong Escherichia coli
表面活性剂具有细胞毒性,如诱导革兰氏阳性菌和革兰氏阴性菌裂解、抑制细菌生长和改变细胞壁结构和孔隙率等。同时,头孢氨苄作为抗生素具有一定的抑菌效果。所以需要确定经表面活性剂联合头孢氨苄处理的细菌、经头孢氨苄处理的细菌是否具有正常的细胞活性。Surfactants are cytotoxic, such as inducing lysis of Gram-positive and Gram-negative bacteria, inhibiting bacterial growth, and altering cell wall structure and porosity. At the same time, cephalexin as an antibiotic has a certain bacteriostatic effect. Therefore, it is necessary to determine whether the bacteria treated with surfactant combined with cephalexin and the bacteria treated with cephalexin have normal cell activity.
①收集在37℃、60rpm有氧条件下正常培养4h的大肠杆菌菌液。①Collect the Escherichia coli bacteria that was normally cultured for 4 hours under aerobic conditions at 37°C and 60rpm.
②收集在37℃、60rpm有氧条件下90μg/mL头孢氨苄暴露4h(LB培养基中添加头孢氨苄)的大肠杆菌②Collect Escherichia coli exposed to 90 μg/mL cephalexin for 4 h under aerobic conditions at 37°C and 60 rpm (with cephalexin added to LB medium).
③分别收集经过0.001%(W/W)CTAB+90μg/mL头孢氨苄、0.1%(W/W)SDS+90μg/mL头孢氨苄和1%(W/W)Tween-20+90μg/mL头孢氨苄联合暴露4h(LB培养基中添加表面活性剂和头孢氨苄)的大肠杆菌。③ Collect the 0.001% (W/W) CTAB+90 μg/mL cephalexin, 0.1% (W/W) SDS+90 μg/mL cephalexin and 1% (W/W) Tween-20+90 μg/mL cephalexin respectively Co-exposed Escherichia coli (surfactant and cephalexin in LB medium) for 4 h.
④分别取500μL①②③中细菌样品用200μL DAPI染色5min,然后以8000rpm离心5min,收集细菌样品。④ Take 500 μL of bacterial samples in ①②③ and stain with 200 μL of DAPI for 5 min, and then centrifuge at 8000 rpm for 5 min to collect bacterial samples.
⑤将④中细菌颗粒分别重新悬浮在200μL的FM4-64溶液中,0℃培养1分钟,再将悬浮液以8000rpm离心5分钟,收集细菌颗粒并分别重新悬浮于蒸馏水中。⑤ Resuspend the bacterial particles in ④ in 200 μL of FM4-64 solution, incubate at 0°C for 1 minute, and then centrifuge the suspension at 8000 rpm for 5 minutes to collect the bacterial particles and resuspend them in distilled water.
⑥分别用荧光显微镜观察⑤中细菌细胞膜和DNA。⑥The bacterial cell membrane and DNA in ⑤ were observed by fluorescence microscope respectively.
DNA的分布如图5所示,经表面活性剂和抗生素联合作用产生的超长大肠杆菌的DNA比正常细胞、头孢氨苄作用产生的超长细菌都要长,且正常分布在细胞中,沿着大肠杆菌纵向均匀分布。The distribution of DNA is shown in Figure 5. The DNA of ultra-long E. coli produced by the combined action of surfactants and antibiotics is longer than that of normal cells and ultra-long bacteria produced by cephalexin, and is normally distributed in cells. E. coli was evenly distributed longitudinally.
细胞膜的分布如图6所示,经表面活性剂和抗生素联合作用产生的超长大肠杆菌的细胞膜比正常细胞和头孢氨苄作用产生的超长细菌都要长,且连续均匀地分布在大肠杆菌表面,表面形态正常。The distribution of the cell membrane is shown in Figure 6. The cell membrane of the ultra-long E. coli produced by the combined action of surfactants and antibiotics is longer than that of normal cells and the ultra-long bacteria produced by the action of cephalexin, and it is continuously and evenly distributed on the surface of E. coli , the surface morphology is normal.
因此,经表面活性剂与头孢氨苄联合作用的细菌具有正常的细胞活性。Therefore, bacteria treated with surfactant in combination with cephalexin have normal cellular activity.
(3)表面活性剂与细胞相互作用(3) Interaction between surfactants and cells
表面活性剂能与细胞膜相互作用,促进有机物的跨膜运输,提高细胞膜的通透性。表面活性剂与细胞膜上的脂类结构相似,因此表面活性剂很可能通过大量插入细胞膜中与大肠杆菌相互作用,我们通过zeta电位测量来验证这一假设。大肠杆菌的zeta电位与电荷成正比,当表面活性剂大量插入或结合到细胞表面(包括细胞膜和细胞壁)时,zeta电位就会发生变化,对于携带不同电荷的SDS和CTAB,其产生的zeta电位应该是不同的。Surfactants can interact with cell membranes, promote the transmembrane transport of organic matter, and improve the permeability of cell membranes. Surfactants are structurally similar to lipids on cell membranes, so it is likely that surfactants interact with E. coli through bulk insertion into the cell membrane, a hypothesis we tested with zeta potential measurements. The zeta potential of Escherichia coli is proportional to the charge. When a large amount of surfactant is inserted or bound to the cell surface (including the cell membrane and cell wall), the zeta potential will change. For SDS and CTAB with different charges, the zeta potential generated by the zeta potential will change. should be different.
①收集在37℃、60rpm有氧条件下正常培养4h的大肠杆菌菌液。①Collect the Escherichia coli bacteria that was normally cultured for 4 hours under aerobic conditions at 37°C and 60rpm.
②收集在37℃、60rpm有氧条件下90μg/mL头孢氨苄暴露4h(LB培养基中添加头孢氨苄)的大肠杆菌。② Collect Escherichia coli exposed to 90 μg/mL cephalexin for 4 h (with cephalexin added to LB medium) under aerobic conditions at 37°C and 60 rpm.
③分别收集在37℃、60rpm有氧条件下经过0.001%(W/W)CTAB+90μg/mL头孢氨苄、0.1%(W/W)SDS+90μg/mL头孢氨苄和1%(W/W)Tween-20+90μg/mL头孢氨苄联合暴露4h(LB培养基中添加表面活性剂和头孢氨苄)的大肠杆菌。③ Collected under aerobic conditions at 37°C and 60 rpm, respectively, after 0.001% (W/W) CTAB+90 μg/mL cephalexin, 0.1% (W/W) SDS+90 μg/mL cephalexin and 1% (W/W) Tween-20+90μg/mL cephalexin was exposed to Escherichia coli for 4h (surfactant and cephalexin were added to LB medium).
④将②和③中大肠杆菌样品分别在8000rpm下离心5min,离心结束后收集细菌颗粒并使其重新悬浮在纯水中。④ Centrifuge the Escherichia coli samples in ② and ③ at 8000 rpm for 5 min respectively. After the centrifugation, collect bacterial particles and resuspend them in pure water.
⑤用Zeta-PALS(ZETAPALS/BI-200SM,Brookhaven,USA)分别测量①④中大肠杆菌的细胞膜表面电位,在相同的实验条件下测量三次。⑤ The cell membrane surface potentials of E. coli in ① and ④ were measured with Zeta-PALS (ZETAPALS/BI-200SM, Brookhaven, USA) respectively, and the measurements were carried out three times under the same experimental conditions.
结果如图7所示,无论是经头孢氨苄单独处理的大肠杆菌,还是表面活性剂与头孢氨苄联合处理后的大肠杆菌,它们细胞膜表面的Zeta电位都比未经处理的大肠杆菌的Zeta电位要低。同时,头孢氨苄单独处理的大肠杆菌的zeta电位发生了明显变化。但是,表面活性剂和头孢氨苄处理的大肠杆菌样品的zeta电位与头孢氨苄单独处理的大肠杆菌样品的zeta电位几乎一致。The results are shown in Figure 7. Whether it is E. coli treated with cephalexin alone or E. coli treated with surfactant and cephalexin in combination, the Zeta potential of the cell membrane surface is higher than that of untreated E. coli. Low. At the same time, the zeta potential of E. coli treated with cephalexin alone changed significantly. However, the zeta potentials of the E. coli samples treated with surfactant and cephalexin were almost identical to those of the E. coli samples treated with cephalexin alone.
以上结果表明,表面活性剂并没有插入或结合在细胞表面,没有改变大肠杆菌的正常功能。The above results indicated that the surfactant did not insert or bind to the cell surface and did not change the normal function of E. coli.
对比例1传统技术制造超长大肠杆菌Comparative Example 1 Traditional technology to manufacture ultra-long Escherichia coli
①将大肠杆菌接种到含有10g/L氯化钠、5g/L酵母提取物和10g/L胰蛋白胨,pH值为7.0的LB培养基中,并在37℃、60rpm有氧条件下过夜培养12h(采用250mL锥形瓶,下同)。①Escherichia coli was inoculated into LB medium containing 10g/L sodium chloride, 5g/L yeast extract and 10g/L tryptone, pH 7.0, and cultured overnight at 37°C and 60rpm under aerobic conditions for 12h (Use a 250mL conical flask, the same below).
②将培养12h且吸光值为0.5(OD=0.5)的菌液用培养基稀释1000倍,将稀释的大肠杆菌接种到LB培养基中,37℃、60rpm有氧再培养2h。② Dilute the bacterial liquid cultured for 12 hours and the absorbance value is 0.5 (OD=0.5) by 1000 times with the medium, inoculate the diluted E.
③将②中细菌分别接种到80μg/mL头孢氨苄、90μg/mL头孢氨苄和100μg/mL头孢氨苄的LB培养基中,37℃、60rpm有氧培养4h,培养结束测量细菌长度。③ Inoculate the bacteria in ② into the LB medium of 80 μg/mL cephalexin, 90 μg/mL cephalexin and 100 μg/mL cephalexin respectively, and incubate them aerobic at 37°C and 60 rpm for 4 hours, and measure the bacterial length after the culture.
④将②中细菌分别接种到80μg/mL头孢氨苄、90μg/mL头孢氨苄和100μg/mL头孢氨苄LB培养基中,37℃、60rpm有氧培养8h,培养结束测量细菌长度。④ The bacteria in ② were inoculated into 80 μg/mL cephalexin, 90 μg/mL cephalexin and 100 μg/mL cephalexin LB medium respectively, and aerobic culture was carried out at 37°C and 60 rpm for 8 h, and the bacterial length was measured after the culture was completed.
⑤分别将③和④不同浓度头孢氨苄处理的大肠杆菌每组随机抽取50株,采用电镜测量长度。长度计算方法同实施例4步骤(1)。⑤ Fifty strains of Escherichia coli treated with different concentrations of cephalexin in ③ and ④ were randomly selected from each group, and the length was measured by electron microscope. The length calculation method is the same as the step (1) of
结果如图8和9所示,头孢氨苄的最佳处理浓度为90μg/mL,最佳处理时间为4h。由于头孢氨苄具有一定的细胞毒性,导致培养后细胞数量下降。培养时间过长(8小时),头孢氨苄耗尽,浓度下降,导致延长结果消失(图9c)。说明头孢氨苄的浓度是获得超长大肠杆菌的关键,需要通过精准的培养时间控制,即随着培养时间的延长,大肠杆菌逐渐增长,同时里面的头孢氨苄的量逐渐减少。在头四个小时时间内,头孢氨苄的量还处于亚致死剂量,表现为大肠杆菌仍在不断增长。过了四个小时,随着头孢氨苄的量减少超过了有效浓度,大肠杆菌逐渐恢复。严格控制头孢氨苄的衰减时间,才能最大化获得超长的大肠杆菌。此外我们对传统方法制备的超长大肠杆菌(步骤③所得)进行了电镜测量,测量结果发现,超长大肠杆菌为1微米左右宽的长细丝状,其长度比普通大肠杆菌延长了近百倍(图10)。同时也发现,超长大肠杆菌仅仅占据所有大肠杆菌总量的很少一部分,绝大多数大肠杆菌仍呈未延长状态。The results are shown in Figures 8 and 9, the optimal treatment concentration of cephalexin is 90 μg/mL, and the optimal treatment time is 4h. Due to the cytotoxicity of cephalexin, the number of cells decreased after culture. Excessive incubation time (8 hours) resulted in depletion of cephalexin and a decrease in concentration, resulting in the disappearance of the prolonged results (Fig. 9c). It shows that the concentration of cephalexin is the key to obtaining ultra-long E. coli, which needs to be controlled by precise incubation time, that is, as the incubation time prolongs, the E. coli gradually increases, and the amount of cephalexin in it gradually decreases. During the first four hours, the amount of cephalexin was still sublethal, as evidenced by the continued growth of E. coli. After four hours, the E. coli gradually recovered as the amount of cephalexin decreased beyond the effective concentration. Strict control of the decay time of cephalexin can maximize the acquisition of ultra-long E. coli. In addition, we carried out electron microscope measurement on the ultra-long E. coli (obtained in step 3) prepared by the traditional method. The measurement results found that the ultra-long E. coli was a long filament with a width of about 1 micrometer, and its length was nearly a hundred times longer than that of ordinary E. coli (Figure 10). At the same time, it was also found that the ultra-long E. coli only accounted for a small part of the total amount of all E. coli, and the vast majority of E. coli were still in an unextended state.
对比例2Comparative Example 2
将实施例1步骤①②③中摇菌的速度分别改为转数为0、30rpm和200rpm,其余条件完全相同,制备超长大肠杆菌。将实施例1步骤①②③中摇菌的容器分别改为50mL离心管、500mL和1000mL锥形瓶,其余条件完全相同,制备超长大肠杆菌。Change the speed of shaking bacteria in steps ①②③ in Example 1 to 0, 30 rpm and 200 rpm respectively, and the other conditions are exactly the same to prepare ultra-long Escherichia coli. Change the container for shaking bacteria in steps ①②③ of Example 1 to 50mL centrifuge tubes, 500mL and 1000mL conical flasks respectively, and the other conditions are exactly the same to prepare ultra-long Escherichia coli.
结果证明,摇菌时转数不足或者静止培养(转数为0)会导致大肠杆菌生长缓慢,无法得到足够数量的大肠杆菌;另一方面,摇菌速度过快,则导致大肠杆菌最长长度变短。随着盛菌器皿口径的增加,相同的转数产生的机械剪切力效果大不相同。在60rpm左右时,使用250mL锥形瓶摇菌方能达到制备超长大肠杆菌的目的。若使用口径更大的盛菌器,应减少转数,以免过大的机械碰撞导致细菌死亡或者导致超长大肠杆菌断裂;若使用口径更小的盛菌器,应相应增大转数。The results proved that insufficient number of revolutions or static culture (the number of revolutions is 0) when shaking bacteria will lead to slow growth of E. coli, and a sufficient number of E. coli cannot be obtained; on the other hand, if the speed of shaking bacteria is too fast, it will lead to the longest length of E. coli shorten. With the increase of the diameter of the bacteria-containing vessel, the mechanical shearing force produced by the same number of revolutions is very different. At about 60 rpm, the purpose of preparing ultra-long E. coli can be achieved only by shaking the bacteria in a 250 mL conical flask. If a larger diameter bacteria container is used, the number of revolutions should be reduced to avoid excessive mechanical collision leading to bacterial death or rupture of super-long E. coli; if a smaller diameter bacteria container is used, the number of revolutions should be increased accordingly.
对比例3Comparative Example 3
①将大肠杆菌(E.coli pD1B10、E.coli BL21、E.coli MG1655品系)分别接种到含有10g/L氯化钠、5g/L酵母提取物和10g/L胰蛋白胨,pH值为7.0的LB培养基中,并在37℃、60rpm有氧条件下过夜培养12h(采用250mL锥形瓶,下同)。①Escherichia coli (E.coli pD1B10, E.coli BL21, E.coli MG1655 strains) were inoculated into pH 7.0 containing 10g/L sodium chloride, 5g/L yeast extract and 10g/L tryptone respectively LB medium, and cultured at 37° C. and 60 rpm under aerobic conditions for 12 h overnight (using a 250 mL conical flask, the same below).
②将培养12h且吸光值为0.5(OD=0.5)的菌液用培养基稀释1000倍,将稀释的大肠杆菌接种到LB培养基中,37℃、60rpm有氧再培养2h。② Dilute the bacterial liquid cultured for 12 hours and the absorbance value is 0.5 (OD=0.5) by 1000 times with the medium, inoculate the diluted E.
③将②中细菌分别接种到30μg/mL、45μg/mL、60μg/mL、75μg/mL、90μg/mL、105μg/mL、120μg/mL的头孢氨苄的LB培养基中,37℃、60rpm有氧培养4h,培养结束测量细菌长度。③ The bacteria in ② were inoculated into the LB medium of cephalexin of 30 μg/mL, 45 μg/mL, 60 μg/mL, 75 μg/mL, 90 μg/mL, 105 μg/mL and 120 μg/mL, respectively, at 37 °C, 60 rpm aerobic After culturing for 4 h, the bacterial length was measured at the end of the culture.
结果如图11所示,不同大肠杆菌品系制备超长大肠杆菌所需使用的头孢氨苄的浓度不同。The results are shown in FIG. 11 , the concentrations of cephalexin required for the preparation of ultralong Escherichia coli by different Escherichia coli strains are different.
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。The above-mentioned embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited by the above-mentioned embodiments, and any other changes, modifications, substitutions, combinations, The simplification should be equivalent replacement manners, which are all included in the protection scope of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010721564.XA CN111826334A (en) | 2020-07-24 | 2020-07-24 | A kind of super-long Escherichia coli and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010721564.XA CN111826334A (en) | 2020-07-24 | 2020-07-24 | A kind of super-long Escherichia coli and its preparation method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111826334A true CN111826334A (en) | 2020-10-27 |
Family
ID=72925230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010721564.XA Pending CN111826334A (en) | 2020-07-24 | 2020-07-24 | A kind of super-long Escherichia coli and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111826334A (en) |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54126722A (en) * | 1978-03-23 | 1979-10-02 | Toyo Jozo Co Ltd | Slow release antibiotic tablet |
GB1598062A (en) * | 1977-03-31 | 1981-09-16 | Sanraku Ocean Co | Antibiotic and its antibacterial derivatives |
US20010013931A1 (en) * | 2000-02-14 | 2001-08-16 | Shimadzu Corporation | Double beam spectrophotometer |
CN1390134A (en) * | 1999-09-14 | 2003-01-08 | 新眼界诊断公司 | The use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses |
US20030096766A1 (en) * | 1996-01-25 | 2003-05-22 | Mclean Allan Joseph | Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria |
EP1750688A1 (en) * | 2004-04-30 | 2007-02-14 | Allergan, Inc. | Steroid intraocular implants having an extended sustained release for a period of greater than 2 months |
US8163896B1 (en) * | 2002-11-14 | 2012-04-24 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
WO2014179784A2 (en) * | 2013-05-03 | 2014-11-06 | Microbiotix, Inc. | Antimicrobial potentiators |
EP2970921A1 (en) * | 2013-03-15 | 2016-01-20 | aTyr Pharma, Inc. | Histidyl-trna synthetase-fc conjugates |
CN105820053A (en) * | 2016-04-23 | 2016-08-03 | 黄亦琼 | Pharmaceutical composition of cefalexin and application of pharmaceutical composition in biological medicine |
TW201741331A (en) * | 2016-03-30 | 2017-12-01 | 康華特科技有限公司 | Detecting microbial infection in wounds |
TW201800753A (en) * | 2016-03-30 | 2018-01-01 | 奎立茲梅診斷有限兩合公司 | Detecting microbial infection in wounds |
CN107656056A (en) * | 2017-08-29 | 2018-02-02 | 山东师范大学 | A kind of method increased based on bacterium to the quick microscopy of bacterium |
EP3403097A1 (en) * | 2016-01-15 | 2018-11-21 | DSM IP Assets B.V. | Method for detecting an analyte |
US20190085034A1 (en) * | 2016-03-16 | 2019-03-21 | Tarveda Therapeutics, Inc. | Antibody mimic conjugates and particles |
WO2019142002A1 (en) * | 2018-01-19 | 2019-07-25 | Ucl Business Plc | Compositions for the treatment of a disease of the urinary tract and treatment of a disease involving the intracellular delivery of the particle or a medicament contained therein |
CN112326607A (en) * | 2020-10-16 | 2021-02-05 | 暨南大学 | Low-concentration ROS detection method and application thereof |
-
2020
- 2020-07-24 CN CN202010721564.XA patent/CN111826334A/en active Pending
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1598062A (en) * | 1977-03-31 | 1981-09-16 | Sanraku Ocean Co | Antibiotic and its antibacterial derivatives |
JPS54126722A (en) * | 1978-03-23 | 1979-10-02 | Toyo Jozo Co Ltd | Slow release antibiotic tablet |
US20030096766A1 (en) * | 1996-01-25 | 2003-05-22 | Mclean Allan Joseph | Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria |
CN1390134A (en) * | 1999-09-14 | 2003-01-08 | 新眼界诊断公司 | The use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses |
US20010013931A1 (en) * | 2000-02-14 | 2001-08-16 | Shimadzu Corporation | Double beam spectrophotometer |
US8163896B1 (en) * | 2002-11-14 | 2012-04-24 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
EP1750688A1 (en) * | 2004-04-30 | 2007-02-14 | Allergan, Inc. | Steroid intraocular implants having an extended sustained release for a period of greater than 2 months |
EP2970921A1 (en) * | 2013-03-15 | 2016-01-20 | aTyr Pharma, Inc. | Histidyl-trna synthetase-fc conjugates |
WO2014179784A2 (en) * | 2013-05-03 | 2014-11-06 | Microbiotix, Inc. | Antimicrobial potentiators |
EP3403097A1 (en) * | 2016-01-15 | 2018-11-21 | DSM IP Assets B.V. | Method for detecting an analyte |
US20190085034A1 (en) * | 2016-03-16 | 2019-03-21 | Tarveda Therapeutics, Inc. | Antibody mimic conjugates and particles |
TW201741331A (en) * | 2016-03-30 | 2017-12-01 | 康華特科技有限公司 | Detecting microbial infection in wounds |
TW201800753A (en) * | 2016-03-30 | 2018-01-01 | 奎立茲梅診斷有限兩合公司 | Detecting microbial infection in wounds |
CN105820053A (en) * | 2016-04-23 | 2016-08-03 | 黄亦琼 | Pharmaceutical composition of cefalexin and application of pharmaceutical composition in biological medicine |
CN107656056A (en) * | 2017-08-29 | 2018-02-02 | 山东师范大学 | A kind of method increased based on bacterium to the quick microscopy of bacterium |
WO2019142002A1 (en) * | 2018-01-19 | 2019-07-25 | Ucl Business Plc | Compositions for the treatment of a disease of the urinary tract and treatment of a disease involving the intracellular delivery of the particle or a medicament contained therein |
CN112326607A (en) * | 2020-10-16 | 2021-02-05 | 暨南大学 | Low-concentration ROS detection method and application thereof |
Non-Patent Citations (7)
Title |
---|
MICHAEL T. DAVISON 等: "Immunochemical Demonstration of Zonal Growth of the Cell Envelope of Escherichia coli", 《EUR.J.BIOCHEM.》 * |
SEN HOU等: "Joint effect of surfactants and cephalexin on the formation of Escherichia coli filament", 《ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY》 * |
TAKESHI NISHINO 等: "Morphological Changes in Staphylococcus aureus and Escherichia coli Exposed to Cephalexin", 《JAPAN.J.MICRIBIOL》 * |
何东平 主编: "《油脂工厂设计》", 30 April 2017, 中国轻工业出版社 * |
张志林 等: "β内酞胺类抗生素引起的大肠杆菌形态改变", 《上海第一医学院学报》 * |
王丽平 等: "不同抗生素对大肠杆菌形态的影响及其诱导游离内毒素的释放", 《中国兽医学报》 * |
陈大明等: "合成生物学应用产品开发现状与趋势", 《中国生物工程杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102250790A (en) | Bacterium S2 for efficiently generating biosurfactant and fermentation culture medium thereof | |
Yu et al. | Clay surface modification and its coagulation of red tide organisms | |
CN107236688B (en) | A marine bacterium used for decolorization and flocculation and its decolorization flocculant preparation method | |
Padukone et al. | Microbially induced separation of quartz from calcite using Saccharomyces cerevisiae | |
CN108546656B (en) | A Salt-tolerant Alternating Pseudomonas and Its Application | |
CN108004170B (en) | A kind of Aeromonas strain R1 and preparation method and its application in algaelytic degradation of microcystins | |
Yildiz et al. | Isolation, characterization and phylogenetic analysis of halophilic Archaea from a salt mine in central Anatolia (Turkey) | |
Khan et al. | Bacteriophage-host interaction in the enhanced biological phosphate removing activated sludge system | |
CN101368200B (en) | Medium for Screening of Anaerobic Simultaneous Sulfate Reduction and Denitrification Strains | |
CN107502569B (en) | Composite microbial inoculum for decoloring flocculation and preparation method of flocculant thereof | |
Wei et al. | Decolorization of dye solutions with Ruditapes philippinarum conglutination mud and the isolated bacteria | |
CN111826334A (en) | A kind of super-long Escherichia coli and its preparation method and application | |
JP2003326296A (en) | Porous composite material and production method therefor | |
CN111378592B (en) | Bacillus licheniformis and method for treating malodorous organic wastewater by using same to purify water | |
CN116891809B (en) | An Asian strain of Pseudomonas and microbial agents and applications | |
CN107794238B (en) | BFX-01 strain for high yield of biological flocculant and biological flocculant obtained thereby | |
CN103468598A (en) | Humic acid degrading strain, and screening method and application method thereof | |
RU2767952C1 (en) | Method of producing ferrihydrite nanoparticles | |
CN114292797B (en) | Physarum viscosum and application of microbial flocculant thereof in sewage treatment | |
CN116751753A (en) | Edwardsiella tarda phage with high lytic property and composition and application thereof | |
Polyanskaya et al. | Sizes of bacterial cells in soils determined by cascade filtration technique | |
Suriya et al. | Characterization of Geobacillus stearothermophilus and its application in soil stabilization | |
Yamin et al. | Harvesting Chaetoceros gracilis by flocculation using chitosan | |
RU2615461C1 (en) | Method for elemental amorphous selenium nanoparticles production | |
CN106434484B (en) | Gold orange II degradation bacteria AO7-1 and its microbial inoculum of production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201027 |